Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors

被引:44
作者
Caponigro, F
Formato, R
Caraglia, M
Normanno, N
Iaffaioli, RV
机构
[1] Fdn G Pascale, Natl Tumor Inst Naples, Div Med Oncol B, I-80131 Naples, Italy
[2] Fdn G Pascale, Natl Tumor Inst Naples, Dept Expt Oncol, Expt Pharmacol Unit, I-80131 Naples, Italy
[3] Fdn G Pascale, Natl Tumor Inst Naples, Cell Biol & Preclin Models Unit, I-80131 Naples, Italy
关键词
epidermal growth factor receptor; head and neck cancer; monoclonal antibodies; vascular endothelial growth factor;
D O I
10.1097/01.cco.0000159623.68506.cf
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review To provide an overview of recent clinical trials with monoclonal antibodies targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in head and neck cancer (HNC) and in other tumors. To discuss future therapeutic strategies. Recent findings Cetuximab, a chimeric monoclonal antibody targeting EGFR, has induced improved locoregional control and survival in combination with radiotherapy in a phase III study in locally advanced inoperable HNC. The recent Bowel Oncology with Cetuximab Antibody (BOND) study has shown that the combination of irinotecan and cetuximab yields a better response rate and a longer time to progression with respect to cetuximab monotherapy in irinotecan-refractory metastatic colorectal cancer, pointing to both a cetuximab single-agent activity and a cetuximab potential for reversal of irinotecan resistance. Non - small cell lung cancer and pancreatic cancer represent further areas for cetuximab development. Bevacizumab is a humanized monoclonal antibody that targets VEGF. It is the first antiangiogenic drug to have induced a survival advantage in cancer therapy, within a randomized trial of irinotecan, 5-fluorouracil, leucovorin (IFL) combined with bevacizumab or placebo in metastatic colorectal cancer. The use of bevacizumab in HNC is supported by preclinical evidence of an angiogenic loop; a few clinical trials are exploring the feasibility and the therapeutic potential of a combination of bevacizumab and EGFR-targeted drugs. Summary Monoclonal antibodies targeting EGFR and VEGF represent exciting therapeutic strategies that should be further evaluated both in combination with drugs acting on the same target at a different level and in combination with other antisignaling agents acting on different pathways.
引用
收藏
页码:212 / 217
页数:6
相关论文
共 40 条
[21]  
KYZAS PA, MOD PATHOL
[22]  
LYNCH TJ, 2004, P AN M AM SOC CLIN, V23, P7084
[23]   Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225):: Superiority over single-agent receptor targeting [J].
Matar, P ;
Rojo, F ;
Cassia, R ;
Moreno-Bueno, G ;
Di Cosimo, S ;
Tabernero, J ;
Guzmán, M ;
Rodriguez, S ;
Arribas, J ;
Palacios, J ;
Baselga, J .
CLINICAL CANCER RESEARCH, 2004, 10 (19) :6487-6501
[24]  
MAUER AM, 2004, P AN M AM SOC CLIN, V23, P5539
[25]   Cancer and leukemia group B 90206:: A randomized phase III trial of interferon-α or interferon-α plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma [J].
Rini, BI ;
Halabi, S ;
Taylor, J ;
Small, EJ ;
Schilsky, RL .
CLINICAL CANCER RESEARCH, 2004, 10 (08) :2584-2586
[26]  
ROBERT F, 2003, P AN M AM SOC CLIN, V22, P2587
[27]  
ROSELL R, 2004, P AN M AM SOC CLIN, V23, P7012
[28]  
ROUGIER P, 2004, P AN M AM SOC CLIN, V23, P3513
[29]   Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer [J].
Rowinsky, EK ;
Schwartz, GH ;
Gollob, JA ;
Thompson, JA ;
Vogelzang, NJ ;
Figlin, R ;
Bukowski, R ;
Haas, N ;
Lockbaum, P ;
Li, YP ;
Arends, R ;
Foon, KA ;
Schwab, G ;
Dutcher, J .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3003-3015
[30]   Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [J].
Saltz, LB ;
Meropol, NJ ;
Loehrer, PJ ;
Needle, MN ;
Kopit, J ;
Mayer, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1201-1208